» Articles » PMID: 35153670

An Cell-Based Delivery Platform for Zinc Finger Artificial Transcription Factors in Pre-clinical Animal Models

Abstract

Zinc finger (ZF), transcription activator-like effectors (TALE), and CRISPR/Cas9 therapies to regulate gene expression are becoming viable strategies to treat genetic disorders, although effective delivery systems for these proteins remain a major translational hurdle. We describe the use of a mesenchymal stem/stromal cell (MSC)-based delivery system for the secretion of a ZF protein (ZF-MSC) in transgenic mouse models and young rhesus monkeys. Secreted ZF protein from mouse ZF-MSC was detectable within the hippocampus 1 week following intracranial or cisterna magna (CM) injection. Secreted ZF activated the imprinted paternal in a transgenic reporter mouse and ameliorated motor deficits in a deletion Angelman Syndrome (AS) mouse. Intrathecally administered autologous rhesus MSCs were well-tolerated for 3 weeks following administration and secreted ZF protein was detectable within the cerebrospinal fluid (CSF), midbrain, and spinal cord. This approach is less invasive when compared to direct intracranial injection which requires a surgical procedure.

Citing Articles

Epigenetic editing for autosomal dominant neurological disorders.

Waldo J, Halmai J, Fink K Front Genome Ed. 2024; 6:1304110.

PMID: 38510848 PMC: 10950933. DOI: 10.3389/fgeed.2024.1304110.


Transcriptional reprogramming restores UBE3A brain-wide and rescues behavioral phenotypes in an Angelman syndrome mouse model.

OGeen H, Beitnere U, Garcia M, Adhikari A, Cameron D, Fenton T Mol Ther. 2023; 31(4):1088-1105.

PMID: 36641623 PMC: 10124086. DOI: 10.1016/j.ymthe.2023.01.013.

References
1.
OGeen H, Bates S, Carter S, Nisson K, Halmai J, Fink K . Ezh2-dCas9 and KRAB-dCas9 enable engineering of epigenetic memory in a context-dependent manner. Epigenetics Chromatin. 2019; 12(1):26. PMC: 6498470. DOI: 10.1186/s13072-019-0275-8. View

2.
Flinterman M, Farzaneh F, Habib N, Malik F, Gaken J, Tavassoli M . Delivery of therapeutic proteins as secretable TAT fusion products. Mol Ther. 2008; 17(2):334-42. PMC: 2835060. DOI: 10.1038/mt.2008.256. View

3.
Wang M, Zuris J, Meng F, Rees H, Sun S, Deng P . Efficient delivery of genome-editing proteins using bioreducible lipid nanoparticles. Proc Natl Acad Sci U S A. 2016; 113(11):2868-73. PMC: 4801296. DOI: 10.1073/pnas.1520244113. View

4.
Keute M, Miller M, Krishnan M, Sadhwani A, Chamberlain S, Thibert R . Angelman syndrome genotypes manifest varying degrees of clinical severity and developmental impairment. Mol Psychiatry. 2020; 26(7):3625-3633. PMC: 8505254. DOI: 10.1038/s41380-020-0858-6. View

5.
Kilic U, Kilic E, Dietz G, Bahr M . Intravenous TAT-GDNF is protective after focal cerebral ischemia in mice. Stroke. 2003; 34(5):1304-10. DOI: 10.1161/01.STR.0000066869.45310.50. View